2025 · Poster Presentation · Pharma Partner · Hepatology
25
Total Publications
10
Abstract/Manuscript
1
Oral Presentation
14
Poster Presentation
2025 · Poster Presentation · Northwestern University · Dermatology
Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA.
Read more →2025 · Poster Presentation · Pharma Partner · Dermatology
Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA.
Read more →2025 · Abstract/Manuscript · Yes
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2025 · Abstract/Manuscript · Atopic Dermatitis (AD)
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups.
Read more →2024 · Poster Presentation · Yes · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score.
Read more →2024 · Poster Presentation · Medical University of South Carolina · Dermatology
Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA.
Read more →2024 · Poster Presentation · Atopic Dermatitis (AD) · Dermatology
Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry.
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2024 · Oral Presentation · Yes · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.
Read more →2023 · Abstract/Manuscript · Yes
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Read more →2022 · Poster Presentation · Yes · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH.
Read more →2022 · Poster Presentation · Pharma Partner · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD.
Read more →2022 · Poster Presentation · Yes · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19.
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
Read more →2022 · Abstract/Manuscript · Atopic Dermatitis (AD)
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Read more →2021 · Abstract/Manuscript · Yes
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.
Read more →2021 · Abstract/Manuscript · Yes
Factors Associated with Readmission in the US Following Hospitalization with COVID-19.
Read more →2019 · Poster Presentation · Yes · Methods/Pharmacoepi